- Home
- MGTX vs CYBN Comparison
MGTX vs CYBN Comparison
Compare MGTX & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- CYBN
- Stock Information
- Founded
- MGTX 2015
- CYBN 2019
- Country
- MGTX United States
- CYBN Canada
- Employees
- MGTX N/A
- CYBN N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- CYBN Pharmaceuticals and Biotechnology
- Sector
- MGTX Health Care
- CYBN Health Care
- Exchange
- MGTX Nasdaq
- CYBN Nasdaq
- Market Cap
- MGTX 670.2M
- CYBN 176.5M
- IPO Year
- MGTX N/A
- CYBN N/A
- Fundamental
- Price
- MGTX $7.33
- CYBN $5.99
- Analyst Decision
- MGTX Strong Buy
- CYBN Strong Buy
- Analyst Count
- MGTX 2
- CYBN 3
- Target Price
- MGTX $24.00
- CYBN $85.00
- AVG Volume (30 Days)
- MGTX 276.6K
- CYBN 617.8K
- Earning Date
- MGTX 11-12-2025
- CYBN 11-12-2025
- Dividend Yield
- MGTX N/A
- CYBN N/A
- EPS Growth
- MGTX N/A
- CYBN N/A
- EPS
- MGTX N/A
- CYBN N/A
- Revenue
- MGTX $37,917,000.00
- CYBN N/A
- Revenue This Year
- MGTX $145.67
- CYBN N/A
- Revenue Next Year
- MGTX $167.61
- CYBN N/A
- P/E Ratio
- MGTX N/A
- CYBN N/A
- Revenue Growth
- MGTX 366.84
- CYBN N/A
- 52 Week Low
- MGTX $3.94
- CYBN $4.81
- 52 Week High
- MGTX $8.98
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- MGTX 42.80
- CYBN 38.18
- Support Level
- MGTX $7.21
- CYBN $5.90
- Resistance Level
- MGTX $7.91
- CYBN $6.19
- Average True Range (ATR)
- MGTX 0.35
- CYBN 0.45
- MACD
- MGTX -0.02
- CYBN -0.04
- Stochastic Oscillator
- MGTX 19.89
- CYBN 9.09
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.